Pharmacokinetics and Relative Bioavailability Evaluation of Linezolid Suspension and Tablet Formulations
Helmy, S.A.
Drug Research (Stuttgart 2013. Print) 63(9): 489-494
2013
ISSN/ISBN: 2194-9379 Accession: 077174030
PDF emailed within 1 workday: $29.90
Related References
Helmy, S.A. 2013: Pharmacokinetics and relative bioavailability evaluation of linezolid suspension and tablet formulations Drug Research 63(9): 489-494Degen, J.; Bruno, L.; Seiberling, M.; Schepers, C.; Brickl, R. 1992: Pharmacocinétique et biodisponibilité relative de deux formulations de dipyridamole (75 et 150 mg) après administration d'une prise unique orale à des volontaires sains - Pharmacokinetics and relative bioavailability of two tablet formulations (75 and 150 mg) of dipyridamole given as single dose to healthy male volunteers Comptes Rendus de Therapeutique et de Pharmacologie Clinique (108): 16-21
Helmy, S.A.; El Bedaiwy, H.M. 2014: Pharmacokinetics and comparative bioavailability of domperidone suspension and tablet formulations in healthy adult subjects Clinical Pharmacology in Drug Development 3(2): 126-131
Nath, R.P.; Upton, R.A.; Everhart, E.T.; Cheung, P.; Shwonek, P.; Jones, R.T.; Mendelson, J.E. 1999: Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations Journal of Clinical Pharmacology 39(6): 619-623
Maas, B.; Garnett, W.R.; Comstock, T.J.; Pellock, J.M. 1985: Comparison of the relative bioavailability and pharmacokinetics of carbamazepine tablets and chewable tablet formulations Annals of Neurology 18(3): 379
Fontes-Ribeiro, C.; Nunes, T.; Falcão, A.; Neta, C.; Lima, R.; Tavares, S.; Almeida, L.; Macedo, T.; Soares-da-Silva, P. 2005: Eslicarbazepine acetate (BIA 2-093) : relative bioavailability and bioequivalence of 50 mg/mL oral suspension and 200mg and 800mg tablet formulations Drugs in R&d 6(5): 253-260
Wire, M.B.; Bruce, J.; Gauvin, J.; Pendry, C.J.; McGuire, S.; Qian, Y.; Brainsky, A. 2012: A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS Clinical Therapeutics 34(3): 699-709
Degen, J.; Wölke, E.; Seiberling, M.; Thomann, P.; Völter-Erhardt, H. 1997: Comparison of the relative bioavailability and pharmacokinetics of estrone after oral administration of esterified estrogens in a tablet formulation and an aqueous suspension Arzneimittel-Forschung 47(2): 208-212
Krishna, G.; Ma, L.; Martinho, M.; O'Mara, E. 2012: Single-dose phase i study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension Antimicrobial Agents and ChemoTherapy 56(8): 4196-4201
E.S.attawy, H.; Kassem, A.; Zaghloul, A. 1997: Comparative kinetics and bioavailability of bioadhesives containing or not-containing ketoprofen tablet formulations relative to conventional tablet in humans Pharmaceutical Research (New York) 14(11 Suppl): S249
Ahmed, I.S.; Fatahalla, F.A. 2007: Pilot study of relative bioavailability of two oral formulations of ketoprofen 25 mg in healthy subjects. A fast-dissolving lyophilized tablet as compared to immediate release tablet Drug Development and Industrial Pharmacy 33(5): 505-511
Lücker, P.W.; Wetzelsberger, N.; Schettler, T.; Rogalla, K. 1992: Pharmacokinetics and relative bioavailability of a new chewable, buffered acetylsalicylic acid tablet formulation in comparison to a conventional plain tablet Methods and Findings in Experimental and Clinical Pharmacology 14(10): 805-811
Menssen, H.D.; Quinlan, M.; Kemp, C.; Tian, X. 2019: Relative Bioavailability and Food Effect Evaluation for 2 Tablet Formulations of Asciminib in a 2-Arm, Crossover, Randomized, Open-Label Study in Healthy Volunteers Clinical Pharmacology in Drug Development 8(3): 385-394
Batenhorst, R.L.; Bustrack, J.A.; Bivins, B.A.; Foster, T.S. 1982: Comparative bioavailability of chlorpropamide tablet and suspension formulations Clinical Pharmacy 1(1): 58-61
Kroll, M.; Milbradt, T.; Coors, C.; Zerbe, H.; Hutt, V.; Weber, W. 1991: Evaluation of the pharmacokinetics and relative bioavailability of a newly developed verapamil film coated tablet preparation in healthy volunteers PZ (Pharmazeutische Zeitung) Wissenschaft 136(2): 75-78
Haustein, K.O. 1986: On the pharmacokinetics of 16-acetyl-gitoxin and its bioavailability from pengitoxin-containing tablet formulations Journal of Pharmacokinetics and Biopharmaceutics 14(4): 357-364
Dadashzadeh, S.; Zarghi, A.; Ebrahimian, A.J. 2003: Pharmacokinetics and comparative bioavailability of two diltiazem tablet formulations in healthy volunteers Daru 11(1): 14-18
Aghazadeh-Habashi, A.; Jamali, F. 2008: Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: influence of gastrointestinal dysfunction on the relative bioavailability of two formulations European Journal of Pharmaceutics and Biopharmaceutics: Official Journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik E.V 70(3): 889-894
Sitar, D.S.; Piafsky, K.M.; Ogilvie, R.I. 1976: The relative bioavailability of terbutaline (Bricanyl) elixir and tablet formulations Current Therapeutic Research 19(2): 266-273
Korth-Bradley, J.M.; Parks, V.; Patat, A.; Matschke, K.; Mayer, P.; Fleckenstein, L. 2012: Relative Bioavailability of Liquid and Tablet Formulations of the Antiparasitic Moxidectin Clinical Pharmacology in Drug Development 1(1): 32-37